.png)
TL;DRReference price group (Festbetragsgruppe) is the group of comparable medicines that the Gemeinsame Bundesausschuss (G-BA) forms under §35 SGB V so that one single Festbetrag can be set for the whole group. The group is the object; the Festbetrag is the amount attached to it.
The distinction matters because the two are routinely conflated. The Festbetrag is a number, the reimbursement ceiling the statutory health insurance pays. The reference price group is the question that comes first: which products count as comparable enough to share that ceiling. Grouping decides the field of competitors. Once a product sits inside a group, its price is measured against every other member, and any amount above the group Festbetrag becomes an Aufzahlung the insured person pays. That is why the boundary of a group is contested far more often than the arithmetic of the amount.
§35 Abs. 1 Satz 2 SGB V defines three levels of comparability, the Gruppenstufen. The level fixes how wide the group is and how much clinical judgement went into drawing its edge. Wider comparability captures more products, including patent-protected ones, but is harder to defend.
| Stufe | Legal wording (§35 Abs. 1 Satz 2) | Basis of comparability | Effect on competition and substitution |
|---|---|---|---|
| Stufe 1 | Arzneimittel mit denselben Wirkstoffen | Identical active ingredient (wirkstoffgleich). | The tightest group. Products are interchangeable at the counter, so price competition is direct and pharmacy aut-idem substitution operates inside it. |
| Stufe 2 | pharmakologisch-therapeutisch vergleichbaren Wirkstoffen, insbesondere mit chemisch verwandten Stoffen | Different active ingredients from a comparable pharmacological class, especially chemically related ones. | Broader. Members are not freely interchangeable at the counter, but they compete on the same ceiling. This is the level at which patent-protected products can be captured. |
| Stufe 3 | therapeutisch vergleichbarer Wirkung, insbesondere Arzneimittelkombinationen | Different mechanisms with a comparable therapeutic effect, explicitly including combination products. | The widest. Competition is on therapeutic outcome rather than substance identity; direct substitution generally does not apply. |
Stufe 2 and Stufe 3 carry a statutory guardrail (§35 Abs. 1 Satz 5): the grouping must not restrict therapeutically necessary prescribing options, and medically required alternatives have to remain available. Reserve antibiotics may be left out of grouping, and age-appropriate paediatric forms and strengths stay out under §35 Abs. 1a SGB V.
Two bodies act in sequence, and the group is where the first one does its work. The G-BA never sets the amount; the GKV-Spitzenverband never draws the group.
Membership also drives what happens downstream in dispensing and procurement. Within a wirkstoffgleiche group the cheapest available packs are what a pharmacy is steered toward, which is the same economic logic that the four-cheapest rule and Rabattverträge exploit. The group defines the peer set; those rules pick winners inside it.
Yes, and the carve-out is the most consequential membership rule for manufacturers. §35 Abs. 1 Satz 6 SGB V exempts from Stufe 2 and Stufe 3 groups those Arzneimittel mit patentgeschützten Wirkstoffen, deren Wirkungsweise neuartig ist oder die eine therapeutische Verbesserung, auch wegen geringerer Nebenwirkungen, bedeuten. A substance stays neuartig for as long as the first substance marketed in its group remains patent-protected (Satz 7). A patent-protected but therapeutically unremarkable analogue preparation gets no such shelter and can be grouped.
There is a second route into a group that runs through AMNOG. Under §35a Abs. 4 SGB V, where the benefit assessment finds no therapeutic improvement, the medicine is assigned in the G-BA resolution to the Festbetragsgruppe of pharmacologically-therapeutically comparable products, a Stufe 2 group. A separate legal challenge against that assignment is inadmissible under §35a Abs. 8 SGB V.
pharmazie.com does not create the grouping, it consolidates the licensed data that reflects it. The group and the amount that applies to each member reach the platform through the licensed ABDA article master data, keyed to the PZN.
One honest limitation: the platform shows which group an article belongs to and the amount that applies, not why the G-BA drew the group boundary where it did. The reasoning behind a grouping and the exact scope of each Stufe live in the G-BA decision documents and Anlage IX/X of the Arzneimittel-Richtlinie. To apply the group, the data field is enough; to argue about a group's cut, the G-BA source is where you go.
